About Biogen
Biogen (NASDAQ:BIIB) operates in the biotechnology sector, focusing on developing therapies for neurological and neurodegenerative diseases. This company is renowned for its work in multiple sclerosis (MS) treatments and has expanded its research and product portfolio to include treatments for Alzheimer's disease, spinal muscular atrophy (SMA), and other serious neurological disorders. With a strong commitment to innovative science, its objectives include advancing the boundaries of neuroscience, improving the lives of those affected by serious diseases, and pursuing a sustainable research and development pipeline. Biogen's projects span from early discovery stages to late-stage clinical trials, aiming to address some of the most challenging unmet medical needs.
Snapshot
Operations
Produtos e/ou serviços de Biogen
- Tecfidera, an oral medication for treating multiple sclerosis, aiming to slow disease progression and reduce relapses.
- Spinraza, the first approved treatment for spinal muscular atrophy, enhancing motor function and survival.
- Tysabri, an infused treatment for multiple sclerosis and Crohn's disease, focusing on reducing flare-ups and slowing disease progression.
- Vumerity, a next-generation treatment for multiple sclerosis, designed to offer a favorable gastrointestinal profile.
- Aduhelm, the first approved Alzheimer's disease modifying therapy, targeting amyloid beta plaques in the brain.
- Plegridy, a pegylated interferon beta used for treating multiple sclerosis, administered via injection to reduce disease activity.
equipe executiva do Biogen
- Mr. Christopher A. ViehbacherPresident, CEO & Director
- Ms. Nicole MurphyExecutive VP and Head of Pharmaceutical Operations & Technology
- Ms. Susan H. Alexander Esq.Executive VP & Chief Legal Officer
- Dr. Priya Singhal M.D., M.P.H.Executive VP & Head of Development
- Ms. Robin C. KramerExecutive VP & CFO
- Mr. Sean GodboutChief Accounting Officer & Global Corporate Controller
- Mr. Guy HadariChief Information Officer
- Mr. Tim Power M.B.A., Ph.D.Head of Investor Relations
- Mr. Adam Keeney Ph.D.Executive VP & Head of Corporate Development
- Dr. Ginger Gregory Ph.D.Executive VP & Chief Human Resources Officer